VANCOUVER, BC / ACCESSWIRE / February 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) is pleased to report an update on its commercialization plan for its ...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)( FSE:4XT) ("XPhyto" or the "Company") is pleased to report the results of its ...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product ...
SAN DIEGO -- The rotigotine patch (Neupro) appeared to objectively improve sleep quality in patients with Parkinson's disease with self-reported sleep complaints, Italian researchers said here. Based ...
May 1, 2012 (New Orleans, Louisiana) — A transdermal patch that delivers 8 mg of the dopamine-receptor agonist rotigotine (Neupro, UCB) in a once-daily, single application is the lowest effective dose ...
BioNxt Solutions (OTCQB:BNXTF) has executed an agreement to carry out comparative drug absorption study for its transdermal (TDS) Rotigotine patch for the treatment of Parkinson's disease. The company ...
January 10, 2007 — Transdermal rotigotine, a dopamine agonist, is effective in controlling symptoms of early-stage Parkinson's disease (PD), a new study suggests. The multicenter, randomized, ...
A new professional intelligence report published by Market.us with the title “The Global Rotigotine Transdermal Patches Market” has the ability to help the decision-makers in the most important market ...
Global Rotigotine Transdermal Patches Market 2020-2029 attempts to offer significant and thoughtful insights into the current market situation and emerging growth dynamics. The report on Rotigotine ...
May 31 -- FRIDAY, May 30 (HealthDay News) -- Skin patches that contain the drug rotigotine help relieve restless legs syndrome (RLS), according to a German study. Dopaminergic drugs -- which stimulate ...
VANCOUVER, BC / ACCESSWIRE / February 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) is pleased to report an update on its commercialization plan for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results